UNICA IRIS Institutional Research Information System

CHESSA, LUCHINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 206.564
NA - Nord America 8.127
AS - Asia 1.540
SA - Sud America 32
AF - Africa 29
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 6
Totale 216.322
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 204.067
US - Stati Uniti d'America 8.072
CN - Cina 914
SE - Svezia 734
UA - Ucraina 724
SG - Singapore 333
DE - Germania 275
GB - Regno Unito 229
FI - Finlandia 226
FR - Francia 99
VN - Vietnam 79
CA - Canada 49
IN - India 45
NL - Olanda 42
KR - Corea 37
RU - Federazione Russa 23
AU - Australia 22
IE - Irlanda 22
HK - Hong Kong 21
CZ - Repubblica Ceca 17
BR - Brasile 16
IR - Iran 16
AT - Austria 15
BE - Belgio 15
TR - Turchia 15
TW - Taiwan 14
ES - Italia 13
CH - Svizzera 10
CO - Colombia 10
IL - Israele 10
MY - Malesia 10
DK - Danimarca 8
IQ - Iraq 8
RO - Romania 8
ZA - Sudafrica 8
BD - Bangladesh 7
ID - Indonesia 6
EG - Egitto 5
JP - Giappone 5
BG - Bulgaria 4
MX - Messico 4
PE - Perù 4
PK - Pakistan 4
PT - Portogallo 4
RS - Serbia 4
UG - Uganda 4
AE - Emirati Arabi Uniti 3
AP - ???statistics.table.value.countryCode.AP??? 3
EU - Europa 3
LT - Lituania 3
LV - Lettonia 3
MK - Macedonia 3
NG - Nigeria 3
NO - Norvegia 3
SI - Slovenia 3
TH - Thailandia 3
HU - Ungheria 2
KE - Kenya 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
PH - Filippine 2
AL - Albania 1
AR - Argentina 1
BF - Burkina Faso 1
BJ - Benin 1
CG - Congo 1
CY - Cipro 1
DZ - Algeria 1
EC - Ecuador 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
JO - Giordania 1
KZ - Kazakistan 1
LB - Libano 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
MU - Mauritius 1
PA - Panama 1
PL - Polonia 1
SD - Sudan 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
UZ - Uzbekistan 1
Totale 216.322
Salva come PNG Salva come JPEG
Città #
Cagliari 197.683
Uta 4.969
Fairfield 915
Woodbridge 783
Chandler 734
Boardman 634
Houston 596
Nyköping 520
Ashburn 513
Ann Arbor 408
Jacksonville 392
Wilmington 348
Seattle 344
Cambridge 294
Dearborn 192
Boston 181
Nanjing 146
Shanghai 144
Singapore 144
Santa Clara 138
Beijing 133
Helsinki 126
New York 109
Rome 109
Milan 80
San Diego 79
Dong Ket 78
Redwood City 70
Nanchang 50
Guangzhou 45
Los Angeles 39
Jiaxing 38
Hebei 37
Shenyang 37
Norwalk 35
London 32
Changsha 31
Washington 27
Paris 25
Seoul 25
Tianjin 25
Sassari 23
Mountain View 22
Orange 22
San Mateo 22
Toronto 22
Verona 20
Nottingham 19
Hong Kong 16
Wuhan 16
Atlanta 15
Jinan 14
Kunming 14
Bari 13
Brussels 13
Dublin 13
Munich 13
Auburn Hills 12
Frankfurt am Main 12
Naples 12
Pune 12
Redmond 12
Bergamo 11
Borås 11
Taizhou 11
Vienna 11
Brescia 10
Brno 10
Florence 10
Genova 10
Hefei 10
Ningbo 10
Taipei 10
Ferrara 9
Saint Petersburg 9
Dallas 8
Gyeongsan-si 8
Huntingdon 8
Leawood 8
Olbia 8
Palermo 8
Phoenix 8
Zhengzhou 8
Amsterdam 7
Augusta 7
Bogazici 7
Bogotá 7
Chicago 7
Napoli 7
Nuoro 7
Padova 7
Renton 7
Santadi 7
Turin 7
Falls Church 6
Porto Torres 6
Shenzhen 6
Täby 6
Bengaluru 5
Chiswick 5
Totale 211.952
Salva come PNG Salva come JPEG
Nome #
Comparing the responses of countries and National Health Systems to the COVID-19 pandemic: a critical analysis with a case-report series 20.524
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.383
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.241
Gastrointestinal Coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management 3.116
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ? 3.049
HLA-G is highly expressed by plasma cells infiltrating hepatic tissue of patients affected by autoimmune hepatitis 3.016
Altered profile of salivary proteins in patients with Autoimmune Hepatitis 2.819
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis 2.711
Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible? 2.686
Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study 2.602
Impact of natural killer (NK) cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients 2.595
Hippocampal axis dysfunction evaluation by Rey-Osterrieth Complex figure test (RCFT) should be included in minimal hepatic encephalopathy (MHE) assessment 2.549
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis 2.462
IMPACT OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS ON PROGRESSION OF HEPATOCELLULAR CARCINOMA 2.409
Behavior of bone mass in long-term HAART patients 2.369
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI 2.348
Association of chronic hepatitis C with recurrent brief depression 2.344
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma 2.284
INFLUENZA DEI POLIMORFISMI DELL’INTERFERONE LAMBDA NELLA STORIA NATURALE DELLA INFEZIONE CRONICA DA HBV: COINCIDENZA O REALTÀ? 2.203
Role of HLA-G in autmoimmune hepatitis 2.182
Safety and efficacy of direct-acting antivirals in transfusion-dependent thalassemic patients with chronic hepatitis C 2.042
Dynamics of TT virus infection in a cohort of HCV-infected patients achieving sustained virologic responce after treatment with direct-acting antivirals 2.040
Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis 2.031
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in patients with chronic HCV infection treated with direct antiviral agents 1.929
A multivariate approach for the brain impairment in patients with liver cirrhosi 1.917
La neopterina uraria come marker di attività immunologica nelle malattie infiammatorie croniche dell’intestino 1.869
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 1.827
Efficacy and tolerability of treatment with the new direct acting antivirals (DAAs) in thalassemic patients with chronic Hepatitis 1.806
Is the Inversion in the Trend of the Lethality of the COVID-19 in the Two Hemispheres due to the Difference in Seasons and Weather? 1.779
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 1.754
null 1.742
null 1.710
Evaluation of mild cognitive dysfunction by Montreal Cognitive Assessment test in co-infected HIV-HCV patients treated with the new direct acting antivirals (DAAs) 1.673
Long-latency potential study in minimal hepatic hencephalopaty 1.669
null 1.666
null 1.610
The climate in the European Union and the enlarged European Region is a determinant of the COVID-19 case fatality ratio 1.571
SAFETY AND EFFICACY OF PEG-IFN alpha 2a AND RIBAVIRIN FOR TREATMENT OF HEPATITIS C IN SARDINIAN ADULT PATIENTS WITH THALASSEMIA MAJOR: A SINGLE CENTRE REAL LIFE EXPERIENCE 1.563
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 1.561
Multidimensional geriatric assessment in elderly HIV patients 1.536
The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study 1.512
Evolution of the viral quasispecies tracked by sequence analysis during interferon treatment of chronic hepatitis C. 1.501
EVALUATION OF MILD COGNITIVE DYSFUNCTION BY MONTREAL COGNITIVE ASSESSMENT TEST IN PATIENTS WITH CHRONIC HCV INFECTION 1.452
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 1.443
HepaDisk – A new quality of life questionnaire for HCV patients 1.443
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 1.441
null 1.424
Orthotopic liver transplantation in neurological Wilson desease: case report 1.417
The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature 1.377
Individualized long-term treatment of chronic hepatitis C with interferon alpha (IFN alpha)-2a. 1.318
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 1.312
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 1.299
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 1.272
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection 1.267
Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database 1.247
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 1.214
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy 1.211
Evolution of the HCV quasispecies and pattern of response to interferon therapy in patients with chronic hepatitis C 1.210
null 1.208
Can antiretroviral therapy modify the clinical course of HDV infection in HIV positive patients? 1.202
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination 1.167
Real-world data on the treatment of primary biliary cholangitis with obeticholic acid in Italy: the CLEO-AIGO OCA cohort. 1.150
La quasispecie del virus dell’epatite C: implicazioni biologiche e cliniche 1.137
Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination 1.133
Predictive Factors for Liver Disease Progression Following the Direct Acting Antivirals Induced Sustained Virological Response: Data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) Cohort 1.129
Forecasting liver disease burden 1.126
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 1.052
Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy 1.050
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 1.039
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 1.034
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 1.016
Risultati preliminari di uno studio di fase II con Sorafenib in pazienti anziani affetti da epatocarcinoma 998
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 993
Epidemiological and Economic Evaluations According to Daa Treatment Access in Italy Based on Real Life Piter Cohort Data 989
Clinical characterization and economic impact evaluation of antiHCV DAA treatment failure:real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) 985
Long term effectiveness of DAA therapy in patients with chronic HCV and Mixed Cryoglobulinemic Syndrome 971
Optimization of Hepatitis C Virus screening strategies by birth cohort in Italy 966
Forecasting Hepatitis C liver disease burden based on real life data. Does the hidden iceberg matter to reach the World Health Organization elimination goals? 941
L'approccio basato sui casi per la diagnosi di malattie epatiche 930
Mixed cryoglobulinemia: an important but frequently unrecognized and underestimated HCV-related condition in the real life practice 918
Distribution of IL28B polymorphism in a cohort of Italians and immigrants with HCV infection: association with viraemia, stage of fibrosis and response to treatment 889
Previous functional social and behavioral rhythms affect resilience to COVID-19-related stress among old adults 888
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 886
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 867
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 867
Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resources’ Allocation 864
A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population 864
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV Gruppo 857
A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G 847
Iron concentration and distribution in the newborn liver 844
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study 838
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 825
The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis 825
Modeling cost-effectiveness and health gains of a “universal“ versus “prioritized“ hepatitis C virus treatment policy in a real-life cohort 804
Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 797
Gender differences in HCV chronic liver disease: a reallife evaluation in PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) Cohort study. 793
Urinary neopterine as an activity marker in immunological diseases 786
Outcomes of advanced liver disease in patients with chronic hepatitis C with and without HIV coinfection following sustained virological response: a real life evaluation in the PITER cohort 771
EFFICACIA A TOLLERABILITÀ DELLA DUAL THERAPY RALTEGRAVIR+DARUNAVIR/RITONAVIR NELLA PRATICA CLINICA 767
Treatment prioritization according to the EASL HCV CPG 2015: a real-life evaluation on the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 762
Totale 171.322
Salva come PNG Salva come JPEG
Categoria #
all - tutte 275.805
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 275.805
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202028.908 0 0 0 0 12.682 8.108 4.333 886 660 579 545 1.115
2020/202147.853 1.242 1.726 1.799 12.140 9.497 5.470 3.889 3.130 1.499 2.960 2.694 1.807
2021/202213.215 1.217 1.135 703 1.000 958 985 865 724 1.097 996 1.535 2.000
2022/202319.438 2.076 2.643 2.596 1.408 1.692 1.926 893 1.655 1.133 1.086 1.435 895
2023/202422.027 1.023 1.137 1.230 1.719 2.007 3.667 3.457 1.523 1.022 1.463 1.747 2.032
2024/202547.504 7.306 29.122 5.040 4.491 1.545 0 0 0 0 0 0 0
Totale 216.904